MX2016015660A - Composicion basada en una solucion estabilizada de ingredientes activos. - Google Patents

Composicion basada en una solucion estabilizada de ingredientes activos.

Info

Publication number
MX2016015660A
MX2016015660A MX2016015660A MX2016015660A MX2016015660A MX 2016015660 A MX2016015660 A MX 2016015660A MX 2016015660 A MX2016015660 A MX 2016015660A MX 2016015660 A MX2016015660 A MX 2016015660A MX 2016015660 A MX2016015660 A MX 2016015660A
Authority
MX
Mexico
Prior art keywords
stabilized solution
pharmaceutically acceptable
active ingredients
water
salt
Prior art date
Application number
MX2016015660A
Other languages
English (en)
Inventor
Nataliia Mykolaivna Derkach
Original Assignee
Nataliia Mykolaivna Derkach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from UAA201405946A external-priority patent/UA113416C2/uk
Priority claimed from UAU201406108U external-priority patent/UA94395U/uk
Priority claimed from UAA201505330A external-priority patent/UA116892C2/uk
Application filed by Nataliia Mykolaivna Derkach filed Critical Nataliia Mykolaivna Derkach
Publication of MX2016015660A publication Critical patent/MX2016015660A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Abstract

La invención se relaciona con composiciones farmacéuticas (variantes) en base a una solución estabilizada de dos ingredientes activos, en donde dicha solución estabilizada de dos ingredientes activos comprende, como primer ingrediente activo, ácido hialurónico de bajo peso molecular y/o una sal farmacéuticamente aceptable del mismo, en donde la masa molecular de dicho ácido o sal es de desde 100kDa a 400kDa o, en una variante, desde 400 kDa a 2,5 MDa, y, como segundo ingrediente activo, Decametoxina o una sal de la misma soluble en agua, y un estabilizador en la forma de una sal farmacéuticamente aceptable que es capaz de disolverse en agua y de disociarse en soluciones acuosas en cationes metálicos y aniones de residuo ácido, o una mezcla de tales sales, siendo el estabilizador capaz de formar compuestos solubles en agua con el ácido hialurónico y/o una sal farmacéuticamente aceptable del mismo y con la Decametoxina o una sal de la misma soluble en agua, simultáneamente. La solución estabilizada contiene además al menos un aditivo farmacéuticamente aceptable.
MX2016015660A 2014-05-30 2015-06-02 Composicion basada en una solucion estabilizada de ingredientes activos. MX2016015660A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
UAA201405946A UA113416C2 (xx) 2014-05-30 2014-05-30 Стабілізований розчин на основі декаметоксину та гіалуронової кислоти, що має терапевтичну активність, спосіб його одержання та фармацевтична композиція на його основі
UAU201406108U UA94395U (uk) 2014-06-03 2014-06-03 Спосіб одержання стабілізованого розчину на основі декаметоксину та гіалуронової кислоти, що має терапевтичну активність
UAA201505330A UA116892C2 (uk) 2015-05-29 2015-05-29 Фармацевтична композиція
UAA201505327 2015-05-29
PCT/UA2015/000047 WO2015183230A1 (ru) 2014-05-30 2015-06-02 Композиция на основе стабилизированного раствора активных веществ

Publications (1)

Publication Number Publication Date
MX2016015660A true MX2016015660A (es) 2017-07-13

Family

ID=68041370

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015660A MX2016015660A (es) 2014-05-30 2015-06-02 Composicion basada en una solucion estabilizada de ingredientes activos.

Country Status (10)

Country Link
EP (1) EP3153156A4 (es)
CN (1) CN106794140A (es)
BR (1) BR112016028176A2 (es)
CL (1) CL2016003063A1 (es)
EA (1) EA033306B1 (es)
MX (1) MX2016015660A (es)
PL (1) PL420378A1 (es)
RO (1) RO131947A2 (es)
RU (1) RU2016148820A (es)
WO (1) WO2015183230A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2659175C1 (ru) * 2017-04-12 2018-06-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва" Композиция на основе бактериальной целлюлозы и гиалуроновой кислоты
UA116755C2 (uk) * 2017-10-09 2018-04-25 Товариство З Обмеженою Відповідальністю "Науково-Виробниче Об'Єднання "Фарматрон" Фармацевтична композиція у формі супозиторіїв з ранозагоюючою, антиерозійною, протизапальною, антимікробною, протигрибковою, імуномодулюючою та антиоксидантною дією
CN110038027A (zh) * 2018-01-16 2019-07-23 菲利达生技股份有限公司 用于抑制发炎的医药组合物
GB2584074B (en) * 2019-04-16 2021-08-11 Alectrona Pte Ltd Monoterpene phenol derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1116044C (zh) * 1998-06-24 2003-07-30 凌沛学 含有透明质酸钠的防粘连颗粒剂和粉雾剂及其制作方法
CN1302813C (zh) * 2004-12-29 2007-03-07 中国海洋大学 含海藻糖和透明质酸的烧伤用药传递系统及其制备方法
RU2280041C1 (ru) * 2005-04-21 2006-07-20 Общество с ограниченной ответственностью Научно-производственное предприятие "Тульская индустрия ЛТД" Способ получения водорастворимых солевых комплексов гиалуроновой кислоты (варианты)
ITMI20072225A1 (it) * 2007-11-23 2009-05-24 Luso Farmaco Inst "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso"
US8119112B2 (en) * 2008-01-31 2012-02-21 Bausch & Lomb Incorporated Ophthalmic compositions with an amphoteric surfactant and hyaluronic acid
WO2010125069A1 (en) * 2009-04-28 2010-11-04 Pharmasurgics In Sweden Ab Hyaluronic acid for preventing post surgical adhesions

Also Published As

Publication number Publication date
CN106794140A (zh) 2017-05-31
EP3153156A1 (en) 2017-04-12
WO2015183230A9 (ru) 2015-12-23
BR112016028176A2 (pt) 2017-08-22
EA201691825A1 (ru) 2017-02-28
EP3153156A4 (en) 2018-02-14
CL2016003063A1 (es) 2017-08-04
PL420378A1 (pl) 2017-10-23
EA033306B1 (ru) 2019-09-30
RU2016148820A (ru) 2018-07-04
RO131947A2 (ro) 2017-06-30
WO2015183230A1 (ru) 2015-12-03

Similar Documents

Publication Publication Date Title
MX2019001096A (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
MX2022001292A (es) Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos.
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
MX2018010788A (es) Composicion oftalmologica.
WO2017218981A3 (en) Compositions and methods for reducing ocular neovascularization
MX2017014035A (es) Formas solidas novedosas.
MX2016015660A (es) Composicion basada en una solucion estabilizada de ingredientes activos.
PH12018501644A1 (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
PH12017501397A1 (en) (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
PH12019501424A1 (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
TN2017000011A1 (en) Aqueous formulation comprising paracetamol and ibuprofen.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
EA202091561A1 (ru) Фармацевтическая композиция, содержащая фармацевтически приемлемую кислотно-аддитивную соль леналидомида
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
CO2016004668A2 (es) Composición basada en una solución estabilizada de ingredientes activos
WO2015165571A3 (en) Solid oral formulations comprising solid melt dispersions of organic acids in xylitol
UA116892C2 (uk) Фармацевтична композиція
UA102461U (xx) Фармацевтична композиція
UA102464U (xx) Фармацевтична композиція
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.